Detection of Pancreatic Ductal Adenocarcinoma by A qPCR-based Normalizer-free Circulating Extracellular Vesicles RNA Signature
Quick Facts
- Publication title: Detection of Pancreatic Ductal Adenocarcinoma by A qPCR-based Normalizer-free Circulating Extracellular Vesicles RNA Signature
- Journal: J Cancer
- Year: 2021
- DOI: 10.7150/jca.50716
- PMID/PMCID: 33531989; PMC7847660
Research overview
Background: Pancreatic ductal adenocarcinoma (PDAC) is difficult to diagnose and many efforts have been made to evaluate EVs-derived RNAs as biomarkers to predict PDAC. Conclusion: We've developed a qPCR-based, normalizer-free circulating EVs RNA classifier, which could well distinguish PDAC patients from noncancerous controls.
Key findings
Background: Pancreatic ductal adenocarcinoma (PDAC) is difficult to diagnose and many efforts have been made to evaluate EVs-derived RNAs as biomarkers to predict PDAC.
However, lack of robust internal references largely limited their clinical application.
Here we proposed an RNA ratio-based, normalizer-free algorithm to quantitate EVs-derived RNAs in PDAC.
Methods: Differentially expressed RNAs in the training group were identified using "limma" package.
Echo Biotech Role
Echo Biotech's specific contribution should be verified from the full text or internal project record.
Related platforms: To Be Verified
Related services and capabilities: Role Not Identified
References
Original publication: Detection of Pancreatic Ductal Adenocarcinoma by A qPCR-based Normalizer-free Circulating Extracellular Vesicles RNA Signature J Cancer. 2021. DOI: 10.7150/jca.50716. PMID/PMCID: 33531989; PMC7847660.